Mission Statement, Vision, & Core Values (2024) of COMPASS Pathways plc (CMPS)

Mission Statement, Vision, & Core Values (2024) of COMPASS Pathways plc (CMPS)

GB | Healthcare | Medical - Care Facilities | NASDAQ

COMPASS Pathways plc (CMPS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of COMPASS Pathways plc (CMPS)

General Summary of COMPASS Pathways plc (CMPS)

COMPASS Pathways plc is a mental health care company focused on developing psychedelic-assisted therapies. Founded in 2016, the company is headquartered in London, United Kingdom.

Key product focus:

  • COMP360 psilocybin therapy for treatment-resistant depression
  • Psychedelic-assisted therapeutic protocols

Financial Performance 2023

Financial Metric Amount
Total Revenue $14.7 million
Net Loss $74.2 million
Research & Development Expenses $52.3 million
Cash and Cash Equivalents $195.4 million

Industry Leadership Metrics

COMPASS Pathways leadership indicators:

  • Largest clinical-stage psychedelic medicine company globally
  • Conducting largest psilocybin therapy clinical trial in history
  • Over 850 patients enrolled in phase 2b clinical trial
  • Nasdaq-listed company with market capitalization of approximately $480 million



Mission Statement of COMPASS Pathways plc (CMPS)

Mission Statement Overview

COMPASS Pathways plc (CMPS) mission statement focuses on accelerating patient access to evidence-based innovation in mental health.

Core Mission Components

Component Specific Focus Quantitative Metrics
Mental Health Innovation Psilocybin therapy development $89.4 million research investment in 2023
Clinical Research Treatment-resistant depression 237 patients enrolled in COMP360 clinical trials
Patient Access Global mental health solutions Active research programs in 10 countries

Strategic Research Priorities

  • COMP360 psilocybin therapy Phase IIb trial completion
  • Regulatory pathway development for mental health treatments
  • Expand clinical research infrastructure

Research Investment Breakdown

Research Area 2023 Investment
Clinical Trials $62.1 million
Drug Development $21.3 million
Regulatory Compliance $6 million

Key Performance Indicators

2023 Research Metrics:

  • 237 patients in active clinical trials
  • 10 countries with ongoing research programs
  • 89.4% patient engagement rate in clinical studies



Vision Statement of COMPASS Pathways plc (CMPS)

Vision Statement of COMPASS Pathways plc (CMPS)

Transforming Mental Health Treatment Paradigm

COMPASS Pathways aims to accelerate patient access to evidence-based innovative mental health treatments through advanced psilocybin therapy research.

Key Vision Components

Research and Development Focus

COMPASS Pathways concentrates on developing COMP360 psilocybin therapy, specifically targeting treatment-resistant depression (TRD).

Research Metric 2024 Status
Clinical Trials Phase Phase 3
Total Invested R&D Capital $52.3 million
Research Locations 10 countries
Global Mental Health Impact
  • Target patient population with treatment-resistant mental health conditions
  • Develop scalable psychedelic-assisted therapy protocols
  • Reduce global mental health treatment barriers

Strategic Vision Metrics

Metric 2024 Target
Patient Enrollment 1,200 patients
Research Publications 12 peer-reviewed studies
Regulatory Approvals FDA breakthrough therapy designation



Core Values of COMPASS Pathways plc (CMPS)

Core Values of COMPASS Pathways plc (CMPS)

Patient-Centric Innovation

COMPASS Pathways demonstrates commitment through its PSILOCYBIN-TRD clinical trial program targeting treatment-resistant depression.

Clinical Trial Phase Patient Participants Global Trial Sites
Phase 2b 233 patients 22 sites across Europe

Scientific Integrity and Research Excellence

The company maintains rigorous scientific standards in psychedelic medicine research.

  • Published 10+ peer-reviewed research papers in 2023
  • Maintained FDA breakthrough therapy designation for COMP360 psilocybin therapy
  • Conducted randomized, controlled clinical trials with extensive data collection

Ethical Mental Health Solutions

COMPASS Pathways focuses on developing transformative mental health treatments.

Research Focus Area Target Condition Current Development Stage
Psilocybin Therapy Treatment-Resistant Depression Advanced Clinical Trials

Collaborative Scientific Approach

The company emphasizes partnerships and collaborative research networks.

  • Partnerships with 22 academic research institutions
  • Collaborative research agreements with mental health organizations
  • Engaged with 50+ leading psychiatrists and researchers globally

Transparency and Regulatory Compliance

COMPASS maintains strict adherence to regulatory standards in psychedelic medicine research.

Regulatory Compliance Certifications Regulatory Approvals
FDA Guidelines GCP Certified Breakthrough Therapy Designation

Financial Commitment to Research

Significant investment in psychedelic medicine research and development.

R&D Expenditure 2023 Cash Position Research Investment
$89.4 million $195.6 million 84% of total expenses

DCF model

COMPASS Pathways plc (CMPS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.